Real-world experience with clinical management of talquetamab in relapsed/refractory multiple myeloma: a qualitative study of US healthcare providers
This study outlines current real-world practices for talquetamab. Findings indicate variation in the SUD care setting. The 0.8 mg/kg Q2W dosing schedule was most common, although switching to Q4W is a real-world symptom management strategy for some patients with responses to therapy. GPRC5D-related symptom management approaches are evolving; prophylactic use of dexamethasone and nystatin mouthwash or zinc and vitamin B complex may be effective strategies to alleviate oral symptoms. Further real-world evidence is needed to inform optimal dosing schedules while mitigating symptom impact.
Authors
- Samantha Shenoy
- Carolina Schinke (ORCID: https://orcid.org/0000-0002-2699-1741)
- Sandra Mazzoni
- Kelly G. Hawks (ORCID: https://orcid.org/0000-0002-4876-9690)
- Tiffany Richards
- Binod Dhakal (ORCID: https://orcid.org/0000-0002-4377-9742)
- Saurabh Patel (ORCID: https://orcid.org/0000-0001-9472-0188)
- Rachel McDowell
- Amalia DeBrosse
- Peter Okorozo
- Xinke Zhang (ORCID: https://orcid.org/0009-0008-9564-9369)
- Jonathan Bunn
- Cesar Rodriguez
- Hoa H. Le (ORCID: https://orcid.org/0000-0001-6755-1331)
- Sara A. Scott
Institutions
- Cleveland Clinic (US)
- Johnson & Johnson (United States) (US)
- The University of Texas MD Anderson Cancer Center (US)
- Emory University (US)
- University of California, San Francisco (US)
- Medical College of Wisconsin (US)
- Prevea Health (US)
- University of Arkansas for Medical Sciences (US)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- Current Medical Research and Opinion
- Published
- 2024-08-23
- DOI
- https://doi.org/10.1080/03007995.2024.2387183
- Citations
- 9
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 4.09
Funders
- Janssen Biotech